ARS Pharmaceuticals, Inc. (SPRY)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.65
- As of
Kresmion compiles this page from SPRY's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ARS Pharmaceuticals, Inc. (SPRY): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full SPRY dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SPRY on one page. Preview it with sample data, then open it live with a free account.
Preview the SPRY dossierActive events for SPRY
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in SPRY
- mediumEarnings below estimates
Q3-2026: Missed consensus by 11.1%, EPS $-0.36 vs $-0.3239 estimate
- high13F: funds reduced
3 tracked funds reduced SPRY this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 79% of SPRY (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 70% of SPRY (2026Q2)
FREE, NO ACCOUNT
Every event on SPRY, as it fires
You are seeing 5 of 16 events recorded on SPRY since 2026-05-30.
The five above landed across 4 days. The other 11 were recorded on 4 other days. 9 of the 16 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
SPRY positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 82835W108 · 2026Q3 | $751K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SPRY
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on SPRY
SPRY against its peers
SPRY's operating margin of -212.9% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | SPRY | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 84.3M USD | 35.5M USD | 81 | 12 |
| Operating margin | -212.9% | -296.2% | 65 | 12 |
| Net margin | -203.3% | -320.7% | 65 | 12 |
| Return on equity | -149.9% | -40.9% | 19 | 17 |
| 1 year | -49.4% | -19.4% | 18 | 18 |
Peers (19): CCCC, CYDY, RZLT, CRMD, LYEL, YDES, ALEC, IRD, CTNM, EDIT, MPLT, PEPG, PBYI, ALT, ENTA, XFOR, FENC, BNTC, TECX. Left out: TRXB (no annual filing), ASPE (no annual filing), PRTCY (period gap), EIKN (no annual filing), VCRE (no annual filing), SCTX (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (SPRY: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in SPRY on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on SPRY in the last 180 days.
Upstream: SEC EDGAR filings for SPRY
Kresmion, "ARS Pharmaceuticals, Inc. (SPRY) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/SPRY. Upstream data: SEC EDGAR filings for SPRY.
Link to this data (HTML):
<a href="https://kresmion.com/research/SPRY">ARS Pharmaceuticals, Inc. (SPRY) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow SPRY on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to SPRY for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.